Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?

Authors :: Papeix C
Mazoyer J
Maillart E
Bensa C
Dubessy AL
Goujon C
Launay O
Lebrun-Frénay C
Louapre C
Mrejen S
Pourcher V
Rosenheim M
Stankoff B
Vidal JS
Lubetzki C
Source :: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Dec; Vol. 27 (14), pp. 2280-2283. Date of Electronic Publication: 2021 Apr 19.
Publication Year :: 2021
Abstract: Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses.<br />Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV.<br />Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS.<br />Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53-3.30, p = 0.54).<br />Conclusion: These results suggest that YFV does not worsen the course of RR-MS.

Subjects :: Cohort Studies
Humans
Retrospective Studies
Vaccination adverse effects
Multiple Sclerosis epidemiology
Multiple Sclerosis, Relapsing-Remitting epidemiology
Yellow Fever epidemiology
Yellow Fever prevention & control

Full Text Access

Tools